5 days ago
LLY
AnalystsTerence FlynnTerence Flynn's Stock Forecasts
AnalystsTerence Flynn
Sectors:
Analyst Ranking
Top 8%
#367 out of 5115 analysts
Average Return
+15.11%
Win Rate
64%72 out of 112
Risk vs Reward
Poor
Good
Terence Flynn's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arcus Biosciences IncRCUS | +208.70% | $8.28 | $25.56 | 2025-05-09 - 2025-11-26 | Strong Buy |
Translate Bio IncTBIO1 | +147.91% | $15.07 | $37.36 | 2020-10-05 - 2021-09-14 | Strong Buy |
Blueprint Medicines CorpBPMC | +140.20% | $41.34 | $99.30 | 2017-03-13 - 2018-03-13 | Strong Buy |
Eli Lilly & CoLLY | +139.90% | $314.17 | $753.68 | 2023-03-01 - 2024-02-29 | Strong Buy |
Arcus Biosciences IncRCUS | +133.21% | $10.96 | $25.56 | 2025-02-18 - 2025-11-26 | Strong Buy |
Terence Flynn Analyst Color
Get additional color on Terence Flynn's coverage of popular stocks
16 days ago
LLY
2 months ago
LLY
4 months ago
JNJ
5 months ago
RPRX
5 months ago
JNJ
5 months ago
LLY
7 months ago
ABBV
7 months ago
JNJ
8 months ago
LLY
8 months ago
JNJ
8 months ago
ABBV
10 months ago
MRK
10 months ago
JNJ
a year ago
ABBV
a year ago
LLY
a year ago
RPRX
a year ago
ABBV
a year ago
LLY
2 years ago
PFE
2 years ago
LLY
2 years ago
PFE
3 years ago
JNJ
3 years ago
PFE
3 years ago
JNJ
Terence Flynn's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 21 | Strong Buy | $1,290.00 | +16.81% | Maintains | 5 days ago |
Biohaven LtdBHVN | 4 | Strong Buy | $26.00 | +174.26% | Maintains | 11 days ago |
Organon & CoOGN | 11 | Hold | $9.00 | +16.28% | Maintains | 18 days ago |
Amgen IncAMGN | 10 | Hold | $329.00 | -4.52% | Maintains | 24 days ago |
Merck & Co IncMRK | 17 | Hold | $100.00 | -4.43% | Maintains | a month ago |
Johnson & JohnsonJNJ | 25 | Hold | $190.00 | -8.46% | Maintains | a month ago |
Nurix Therapeutics IncNRIX | 6 | Hold | $15.00 | -12.79% | Maintains | a month ago |
Pfizer IncPFE | 19 | Hold | $32.00 | +24.47% | Maintains | 2 months ago |
Royalty Pharma PLCRPRX | 13 | Strong Buy | $54.00 | +35.54% | Maintains | 2 months ago |
Biontech SeBNTX | 5 | Strong Buy | $131.00 | +27.56% | Maintains | 2 months ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | $438.00 | +1.35% | Maintains | 2 months ago |
United Therapeutics CorpUTHR | 11 | Hold | $435.00 | -10.94% | Maintains | 2 months ago |
Alumis IncALMS | 2 | Strong Buy | $22.00 | +187.96% | Maintains | 3 months ago |
Abbvie IncABBV | 18 | Strong Buy | $255.00 | +12.01% | Maintains | 4 months ago |
Bristol Myers Squibb CoBMY | 10 | Strong Sell | $34.00 | -30.96% | Maintains | 5 months ago |
Arvinas IncARVN | 8 | Hold | $11.00 | -11.43% | Maintains | 7 months ago |
Arcus Biosciences IncRCUS | 6 | Strong Buy | $22.00 | -13.93% | Maintains | 7 months ago |
Crispr Therapeutics AgCRSP | 7 | Strong Sell | $32.00 | -39.96% | Maintains | 9 months ago |
Intellia Therapeutics IncNTLA | 5 | Hold | $11.00 | +29.11% | Downgrades | 10 months ago |
Structure Therapeutics IncGPCR | 1 | Strong Buy | $118.00 | N/A | Initiates Coverage On | a year ago |
Blueprint Medicines CorpBPMC | 5 | Strong Buy | $168.00 | N/A | Maintains | 2 years ago |
C4 Therapeutics IncCCCC | 5 | Hold | $8.00 | N/A | Maintains | 2 years ago |
Revance Therapeutics IncRVNC | 7 | Hold | $12.00 | N/A | Maintains | 2 years ago |
Neuehealth IncNEUE | 1 | Strong Buy | $2,880.00 | N/A | Initiates Coverage On | 4 years ago |
Biogen IncBIIB | 2 | Hold | $436.00 | N/A | Maintains | 4 years ago |
Translate Bio IncTBIO1 | 1 | Strong Buy | $342.00 | N/A | Initiates Coverage On | 5 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $40.00 | N/A | Upgrades | 7 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Fibrogen IncFGEN | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.